Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
| Autor: | Naval Daver, Jing Ning, Guillermo Garcia-Manero, Tapan M. Kadia, Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Daewoo Pak, Jabra Zarka, Farhad Ravandi, Marina Konopleva, Fadi Haddad, Zhenya Tang, Keyur P. Patel, Ghayas C. Issa, Elias Jabbour, Gautam Borthakur, Courtney D. DiNardo, Branko Cuglievan, Koji Sasaki, Michael Andreeff |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Methyltransferase Multivariate analysis Adolescent Adverse outcomes Chromosomal translocation Article Young Adult Internal medicine hemic and lymphatic diseases medicine Humans Transplantation Homologous Leukaemia RC254-282 Aged Retrospective Studies Aged 80 and over Gene Rearrangement Adult patients biology business.industry Hematopoietic Stem Cell Transplantation Myeloid leukemia Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hematology Histone-Lysine N-Methyltransferase Middle Aged Prognosis Survival Analysis Leukemia Myeloid Acute KMT2A Mutation biology.protein Female Allogeneic hematopoietic stem cell transplant business Myeloid-Lymphoid Leukemia Protein |
| Zdroj: | Blood Cancer Journal, Vol 11, Iss 9, Pp 1-10 (2021) Blood Cancer Journal |
| ISSN: | 2044-5385 |
| Popis: | Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various translocations causing KMT2Ar are conflicting. Less is known about associated mutations and their prognostic impact. In a retrospective analysis, we identified 172 adult patients with KMT2Ar AML and compared them to 522 age-matched patients with diploid AML. KMT2Ar AML had fewer mutations, most commonly affecting RAS and FLT3 without significant impact on prognosis, except for patients with ≥2 mutations with lower overall survival (OS). KMT2Ar AML had worse outcomes compared with diploid AML when newly diagnosed and at relapse, especially following second salvage (median OS of 2.4 vs 4.8 months, P KMT2Ar AML (t-AML) had worse outcomes compared with de novo KMT2Ar AML (median OS of 0.7 years vs 1.4 years, P P KMT2Ar did not predict survival, unlike age and allo-HSCT. In conclusion, KMT2Ar was associated with adverse outcomes regardless of translocation subtype. Therefore, AML risk stratification guidelines should include all KMT2Ar as adverse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink